choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Tasigna

Tasigna Newsletter
  • All the drugs that lose their U.S. patents in 2025 10 Apr 2025 15:49 GMT

    … outlet specializing in pharmaceutical industry analysis and data … of globally recognized medications set to lose … and bone complications in cancer patients. Together, they … Tasigna (Novartis) Tasigna, used in the treatment of leukemia, is another Novartis drug …

  • Rutgers Cancer Institute Reviews Guidelines for Managing Blood Cancers During Pregnancy 09 Apr 2025 00:54 GMT

    … researchers at Rutgers Cancer Institute Department of Blood … in maternal-fetal medicine. Any treatment decisions should be … along with Rituxan. Treatment of leukemia during pregnancy varies … Phyrago or Sprycel (dasatinib), Tasigna or Danziten (nilotinib), and …

  • Addressing Treatment Gaps in High-Risk CML in Blast Phase 05 Apr 2025 02:47 GMT

    … Medical Oncology, Cleveland Clinic, critical gaps exist in blast-phase treatment … leukemia have a life expectancy of normal individuals or people without cancer … treatment—and multiple newer TKIs in clinical trials … TKIs—nilotinib [Tasigna], dasatinib [Sprycel …

  • October - December 2024 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS) 31 Mar 2025 19:52 GMT

    … selective norepinephrine reuptake inhibitors Tricyclic antidepressants (TCAs) Monoamine oxidase inhibitors (MAOIs … (dasatinib) tablets Tasigna (nilotinib) capsules Sprycel (dasatinib) tablets Drug interaction FDA is evaluating …

  • FDA Approves Scemblix for Some With Newly Diagnosed Chronic Myeloid Leukemia 29 Oct 2024 19:05 GMT

    … Food and Drug Administration (FDA) for the treatment of adults … kinase inhibitor, which included Tasigna (nilotinib), Gleevec (imatinib), … from the ASC4FIRST trial were presented at … treatment paradigm in [chronic myeloid leukemia].” For more news on cancer …

  • What is Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)? 23 Dec 2024 13:33 GMT

    … of acute lymphoblastic leukemia (ALL). The main treatments for Ph+ … is a type of cancer that affects the blood … (Sprycel) imatinib (Gleevec) nilotinib (Tasigna) ponatinib (Iclusig) Ph+ ALL … with chemotherapy. A doctor may also recommend targeted therapy drugs.

  • Asciminib Appears to Benefit All Chronic Myeloid Leukemia Subgroups 10 Dec 2024 22:55 GMT

    … subgroups. CancerNetwork® spoke with Andorsky, medical oncologist, hematologist … generation TKIs: nilotinib [Tasigna], dasatinib [Sprycel], or … ], and also fewer treatment discontinuations, interruptions, or … diagnosed chronic myeloid leukemia in chronic phase …

  • Oncology Drugs, Diagnostics Approved by the FDA in November 2024 02 Dec 2024 16:48 GMT

    … Food and Drug Administration (FDA) for diseases including leukemia, biliary tract cancer and other … medications for chronic myeloid leukemia. This can significantly improve patient adherence to treatment …

  • OncLive’s November Roundup of Key FDA Approvals in Oncology 03 Dec 2024 03:51 GMT

    … Department of Leukemia, Division of Cancer Medicine, at The … treatment paradigm. 11/14: Nilotinib Tablets in Chronic Myeloid Leukemia The FDA … Pharmaceuticals, stated in a news release. “Unlike Tasigna, … agency approved updated drug labeling for fludarabine …

  • Azurity Announces FDA Approval of Danziten Tablets 26 Nov 2024 14:24 GMT

    … MA—Azurity Pharmaceuticals, Inc., announced that the FDA has approved … chromosome positive chronic myeloid leukemia (Ph+ CML) in … CEO of Azurity Pharmaceuticals, Inc. “Unlike Tasigna, the boxed … including patient adherence to treatment. Danziten has the …

Satisfied with the content?

Continue to create your account.